3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
8
Rectal Neoplasms
7
Neoplasm Metastasis
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Neutropenia
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastric Cancer Adenocarcinoma Metastatic
1
First-line Treatment
1
Esophageal Squamous Cell Carcinoma
1
EFS
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Cisplatin
24
Carboplatin
19
Paclitaxel
18
pembrolizumab
12
Gemcitabine
12
Radiotherapy
9
Fluorouracil
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
cemiplimab
6
Platinum
6
Nivolumab
6
Docetaxel
6
Cetuximab
6
1,2-diaminocyclohexaneplatinum II citrate
6
epothilone B
5
anlotinib
5
Sunitinib
5
Pemetrexed
5
Oxaliplatin
5
Everolimus
5
Drug Therapy
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
durvalumab
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Erlotinib Hydrochloride
4
Celecoxib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma
×
trifluridine tipiracil drug combination
×
Clear all
NCT02920476
2022-06-23
UF-STO-LUNG-003
University of Florida
Phase 2
Completed
4 enrolled
8 charts